Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Hsbc Holdings PLC

Key Points

• Hsbc Holdings PLC increased its holdings in Sarepta Therapeutics by 28.7% during the first quarter, owning approximately 0.11% of the company's stock valued at $6.6 million.
• Sarepta's earnings report showed a 68.4% year-over-year revenue increase, with an EPS of $2.02, surpassing analyst expectations by $1.13.
• Analysts have set varied price targets for Sarepta, with a consensus average of $43.50, while eight analysts rated it a "Buy."

Hsbc Holdings PLC boosted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 28.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 103,700 shares of the biotechnology company's stock after purchasing an additional 23,147 shares during the period. Hsbc Holdings PLC owned approximately 0.11% of Sarepta Therapeutics worth $6,618,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Mariner LLC increased its position in shares of Sarepta Therapeutics by 14.8% during the fourth quarter. Mariner LLC now owns 8,042 shares of the biotechnology company's stock worth $978,000 after acquiring an additional 1,035 shares during the last quarter. Jump Financial LLC acquired a new stake in Sarepta Therapeutics during the 4th quarter valued at approximately $221,000. Dimensional Fund Advisors LP increased its holdings in Sarepta Therapeutics by 10.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 310,810 shares of the biotechnology company's stock worth $37,791,000 after purchasing an additional 30,615 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Sarepta Therapeutics by 2.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 241,663 shares of the biotechnology company's stock valued at $29,385,000 after purchasing an additional 5,130 shares in the last quarter. Finally, Coldstream Capital Management Inc. acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $201,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock traded down $0.14 on Friday, reaching $18.20. 22,526,492 shares of the company were exchanged, compared to its average volume of 10,716,794. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -20.92 and a beta of 0.49. Sarepta Therapeutics, Inc. has a 1-year low of $10.41 and a 1-year high of $140.10. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The company's 50-day moving average is $17.72 and its two-hundred day moving average is $46.58.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The firm had revenue of $611.09 million during the quarter, compared to the consensus estimate of $530.66 million. During the same period in the prior year, the business earned $0.07 EPS. The firm's revenue was up 68.4% on a year-over-year basis. As a group, research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SRPT. Bank of America lifted their price target on shares of Sarepta Therapeutics to $17.00 and gave the stock an "underperform" rating in a research note on Wednesday, August 20th. HC Wainwright reissued a "sell" rating on shares of Sarepta Therapeutics in a research report on Monday, August 25th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Sarepta Therapeutics to $12.00 and gave the company a "sell" rating in a research note on Friday, August 15th. Robert W. Baird increased their price target on shares of Sarepta Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Finally, TD Cowen downgraded Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 price target for the company. in a research note on Wednesday, June 18th. Eight investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $43.50.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.